Director, Assistant Controller

$196k - $240k

Location
Boston, MA, US
Workplace
Hybrid
Employment
Full-time

About this role

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis’ most advanced program, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, with multi-indication potential across multiple tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer. Aktis’ second pipeline program, AKY-2519, is a miniprotein radioconjugate targeting B7-H3 expressing tumors, including prostate, lung and other solid tumors. Aktis has a strategic collaboration with Eli Lilly and Company to leverage its miniprotein platform to develop novel radioconjugates outside of Aktis’ proprietary pipeline.

Aktis Oncology is seeking a highly motivated Assistant Controller with a strong background in accounting operations, financial reporting, and internal controls. In this high-impact role, you will report to and be the trusted right hand to the Senior Director, Controller. You will be responsible for managing key accounting activities and the financial close process, leading process improvement initiatives and building strong, collaborative relationships across the organization. Importantly, you will act as the primary accounting partner for R&D teams, establishing an in-depth knowledge of activities to ensure proper controls, accounting and financial disclosure. 

This position is a Boston-based on-site/hybrid role with one day a week in our corporate headquarters.

Responsibilities 

  • Oversee and maintain the general ledger, ensuring all financial transactions are accurately recorded and properly classified.
  • Lead the monthly close process, including preparing and reviewing journal entries, reconciliations, fluctuation analysis, and financial reports.
  • Support the development and implementation of internal controls and maintain evidence of the performance of internal controls to ensure compliance and audit readiness.
  • Assist with the development of scalable accounting policies, processes and systems to support potential future public company reporting, including SOX preparedness.
  • Identify and implement technology-driven improvements in financial processes to enhance efficiency, accuracy, and scalability.
  • Collaborate closely with R&D leaders to establish an in-depth knowledge of functional priorities, workstreams, contracts and external relationships. 
  • Oversee process development and quarterly execution of critical R&D expense accrual and revenue recognition assessments.
  • Together with FP&A, act as a business partner to R&D teams, providing support and guidance as needed to ensure accurate and effective flow of financial information.  

Qualifications

  • Minimum of a Bachelor’s degree with CPA license and 7-10 years related experience required.
  • At least 3-5 years with life science companies.
  • Hands-on experience working in both private and public company settings.
  • Demonstrated knowledge of GAAP and SOX controls.
  • Demonstrated managerial capability in a growing and changing company:
    • ability to initiate and make improvements to processes and procedures; 
    • ability to adapt to changing priorities;
    • ability and desire to supervise, as well as perform the detailed work;
    • ability to focus on detail while understanding the relevance and application of that detail to the larger business at hand.
  • Demonstrated success collaborating within finance and cross-functionally (with particular emphasis on Research, CMC and Clinical teams).
  • Working knowledge and experience with financial systems – NetSuite, Prendio – strongly preferred.
  • Strong, demonstrated workplace skills, including but not limited to:
    • time management – schedules, timelines, task prioritization;
    • communication – written and verbal; ability to coordinate and interact with all levels and functions;
    • analytical and organizational.


Aktis Oncology is an Equal Opportunity Employer and does not discriminate on the basis of race, religion, color, sex, gender identity or expression, sexual orientation, age, disability, national origin, veteran status, or any other basis covered by appropriate law. Aktis Oncology is committed to promoting and maintaining a work environment in which all applicants, employees, and other individuals are treated with dignity and respect free from unlawful harassment, discrimination, or retaliation.

Apply to Aktis Oncology

Clera fills in Aktis Oncology's application for you.

How it works

Open the role in Clera

Sign in, and this role opens on your Clera job board, ready to apply.

Clera fills in the application

Clera fills the form from your profile and resume, and asks what's missing.

Track it in Clera

Each application you send shows up in your Clera tracker, sorted by stage.

Want Clera to find roles for you?

Ask your AI about this role

It knows you. Clera gives it the role.

Does this role fit my profile?

First time? Connect Clera once, about a minute.
One click above pre-fills the connector. Or by hand: Settings > Connectors > Add custom connector, paste https://mcp.getclera.com. Either way, sign in with the account you use on Clera and approve the consent screen.
https://mcp.getclera.com

Sign in with your Clera account. MCP docs

About Aktis Oncology

Aktis Oncology (Nasdaq: AKTS) is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies.

The company has developed a proprietary miniprotein radioconjugate platform designed to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors, while being rapidly cleared from normal organs and tissues to minimize systemic radiation exposure. Aktis’ most advanced pipeline program targets Nectin-4, a miniprotein radioconjugate with multi-indication potential across multiple tumor types. The company also maintains a strategic collaboration with Eli Lilly and Company to develop novel anticancer radiopharmaceuticals for targets outside of Aktis’ proprietary pipeline.

Team size
51-200 employees people
Industry
Biotechnology Research
Workplace
Hybrid
Locations
Boston, Massachusetts, United States